Codexis, Inc. (CDXS) News
Follow Codexis, Inc. (CDXS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Codexis to Report Third-Quarter 2026 Results November 12
EQUITY | Oct 29, 2026, 01:01 PM UTC
M
Codexis Q3'26 earnings preview cites EPS estimate of $(0.10)
Codexis is scheduled to announce Q3'26 results on October 29, with EPS expected at $(0.10).
EQUITY | Oct 28, 2026, 11:05 AM UTC
L
Codexis Shares Gain on Agreement With Undisclosed Drug Innovator
By Connor HartShares of Codexis climbed after the company said it reached an agreement with an undisclosed siRNA drugmaker.The stock rose 4%, to $1.37, in premarket trading Monday. Through Friday's close, shares are down
EQUITY | Sep 28, 2026, 11:01 AM UTC
L
Codexis, Inc. (CDXS) Signs Deal to Supply Stereo-Defined siRNA Fragments
Codexis entered an agreement with a pioneering siRNA innovator to supply stereo-defined oligonucleotide fragments via its ECO Synthesis platform and compare them with SPOS for purity, quality, and ligation performance.Ma
NEWS | Sep 28, 2026, 10:09 AM UTC
L
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. NASDAQ:CDXS, a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pio
NEWS | Sep 28, 2026, 10:08 AM UTC
L
CDXS: ECO Synthesis enables scalable, efficient, and greener siRNA manufacturing for expanding RNA therapeutics
siRNA therapies are rapidly expanding, but traditional manufacturing faces scale and environmental challenges. The ECO Synthesis platform offers scalable, capital-efficient, and environmentally friendly enzymatic product
EQUITY | Sep 10, 2026, 03:07 PM UTC
L
CDXS: ECO Synthesis enables scalable, efficient, and environmentally friendly siRNA manufacturing
siRNA therapies are rapidly expanding, but traditional manufacturing faces scale and environmental challenges. The ECO Synthesis platform offers scalable, aqueous, and stereocontrolled enzymatic production, with signific
EQUITY | Sep 10, 2026, 02:31 PM UTC
L
Codexis to participate in Cantor Global Healthcare Conference 2026
Codexis says it will participate in the Cantor Global Healthcare Conference 2026.
EQUITY | Aug 27, 2026, 01:01 PM UTC
L
CDXS - Codexis Reports Second Quarter 2026 Financial Results
CDXS - Codexis Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 11, 2026, 08:07 PM UTC
L
Codexis Affirms FY2026 Sales Guidance of $72.000M-$76.000M vs $74.099M Est
Codexis (NASDAQ: CDXS ) affirms FY2026 sales outlook from $72.000 million-$76.000 million to $72.000 million-$76.000 million vs $74.099 million estimate.
EARNINGS | Aug 11, 2026, 08:05 PM UTC
L
Codexis Q2 EPS $(0.13) Beats $(0.14) Estimate, Sales $14.915M Beat $14.348M Estimate
Codexis (NASDAQ: CDXS ) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 18.75 percent increase over losses of $(0.16) per share from the same
EARNINGS | Aug 11, 2026, 08:05 PM UTC
L
Codexis Appoints David Butler to Advisory Board
Codexis appoints new advisory board member
EQUITY | Aug 03, 2026, 01:00 PM UTC
H
Crude Oil Down Over 4%; Verizon Raises Earnings Forecast
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 100 points on Friday. The Dow traded up 0.20% to 51,815.71 while the NASDAQ declined 0.13% to 25,105.02. The S&P 500 also rose,
MACRO | Jul 24, 2026, 04:55 PM UTC
H
US Stocks Mixed; American Express Shares Fall Following Q2 Results
U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 0.2% on Friday. Following the market opening Friday, the Dow traded up 0.17% to 51,799.17 while the NASDAQ declined 0.15% to 25,099.23. The S
MACRO | Jul 24, 2026, 01:45 PM UTC
L
Deals priced today • SCTX (Scribe Therapeutics) 8.58M share (up from 7.15M shrs IPO), priced at $15.00 (range was $13 - $15), by Leerink, GS
Deals priced today • SCTX (Scribe Therapeutics) 8.58M share (up from 7.15M shrs IPO), priced at $15.00 (range was $13 - $15), by Leerink, GSCO, GUGG & WELLS • CDXS 16.67M share Spot Secondary, priced at $1.50, by Piper,
EQUITY | Jul 24, 2026, 12:25 PM UTC
L
Codexis falls 20% after pricing $25M stock offering at $1.50/share
Codexis falls 20% after pricing $25M stock offering at $1.50/share
EQUITY | Jul 24, 2026, 05:51 AM UTC
L
CDXS Codexis announces proposed public offering of common stock
CDXS Codexis announces proposed public offering of common stock
EQUITY | Jul 23, 2026, 08:13 PM UTC